Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aethlon Medical Inc

Aethlon Medical's Hemopurifier set to revolutionize cancer therapy and COVID-19 treatment
Current Analysis:
Aethlon Medical, a medical therapeutic company, has advanced two clinical stage devices that are designed to treat life-threatening infectious diseases and cancer called the Hemopurifier. The device is said to be capable of clearing exosomes that spread cancer or other viral infections through multiple mechanisms. The FDA has approved the device and designated it as a "Breakthrough Device" for two independent indications. The medical company is planning to conduct clinical trials in Australia for the use of Hemopurifier in treating solid tumors, head and neck cancer, gastrointestinal cancers, and other cancers.

Forward-Looking Analysis:
Aethlon Medical is also currently testing the efficacy of Hemopurifier in COVID-19 treatments, with the first patient enrolled and having completed the Hemopurifier treatment phase of the protocol earlier this year. The company has launched a wholly-owned subsidiary in Australia formed, which aims to conduct clinical research, seek regulatory approval, and commercialize Hemopurifier. Despite the Hemopurifier being a promising device in cancer and viral infection treatment, Aethlon Medical is facing disruptions in their Hemopurifier supply. However, with the company's innovative and effective technologies, they are set to revolutionize the cancer therapy and COVID-19 treatment industry.

Announcement: AEMD 10-Q Quarterly Report

Form 8-K - Current report - Item 2.02 Item 9.01

Analyst Summary:

Aethlon Medical has reported financial results for its Q3 FY2022, including a cash balance of $17.5 million. The company is continuing to develop its Hemopurifier® therapeutic blood filtration system and recently contracted with NAMSA to direct their planned oncology study for solid tumors failing anti-PD-1 antibodies. The company also hired a new Chief Scientific Officer, Dr. Lee Arnold, who has led product development at five previous companies. Aethlon has ongoing preclinical studies to expand the potential utility of the Hemopurifier, including an mPox experiment and a study of Post-acute Sequelae of COVID-19 infection. The company raised approximately $8.9 million in net proceeds under its ATM agreement with H.C. Wainwright & Co. during the nine months ended December 31, 2022.

Announcement: AEMD 8-K Special Filing

Form 8-K - Current report - Item 8.01 Item 9.01

OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP